Patient P-02157

Synthetic patientMETA-24 · Day 177 · 65–74 · F · baseline S14Open companion preview

Therapy response

Stable

Tolerance

Stable

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

96%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S14
Day 73 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 79 GI-04 recommended — GI Support Protocol GI-04
Day 80 Patient declined — Not now
Day 92 ME-01 recommended — Monitoring Escalation ME-01
Day 93 Patient accepted — Started ME-01 in the companion
Day 96 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 73.

Primary contributors, last 14 days

Treatment adherence-8
Inflammatory activity-3

What helped?

GI Support Protocol GI-04Day 79
Declined by patient
Monitoring Escalation ME-01Day 92
Result: deterioration detected before clinical escalation

LIFE OS recommendation

GI Support Protocol GI-04

92%

probability of meaningful tolerance improvement

284 similar trajectories
88% showed improvement
median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 40/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 72 and rising
- WearableSleep 5.2 h, below personal baseline
Inflammatory signalling ↓40
- BloodInflammatory load index 61
- WearableHRV 35 ms, trending down
Autonomic recovery ↓40
- Wearable1,818 steps/day
- WearableShort sleep window
Drug metabolism and exposure ↑20
- BloodToxicity index 52

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
CYP2D6 Rapid metabolizer
Expected exposure
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 2.7 · butyrate capacity 40/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumLow
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 37 ms
Sleep: 5.3 h
Steps: 2,161
Resting HR: 71 bpm

Daily log: GI score 72, nutritional resilience 32, adherence 38.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02018	37%	S01	GI-04	improved	46
P-02410	33%	S01	GI-04	improved	55
P-02409	29%	S01	SC-12	no change	54
P-02054	28%	S01	CR-01	improved	57
P-02307	18%	S01	—	—	55
P-02598	18%	S01	—	—	53
P-02041	17%	S01	—	—	27
P-02276	17%	S01	—	—	57
P-02437	17%	S01	—	—	64
P-02550	17%	S01	—	—	70
P-02568	17%	S01	—	—	51
P-02087	16%	S01	BR-03	no change	40